Longboard Pharmaceuticals, Inc. (LBPH)
NASDAQ: LBPH · IEX Real-Time Price · USD
20.27
+1.60 (8.57%)
Apr 23, 2024, 4:00 PM EDT - Market closed
Company Description
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases.
The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies.
It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020.
Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
Longboard Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2020 |
| IPO Date | Mar 12, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 50 |
| CEO | Kevin R. Lind |
Contact Details
Address: 4275 Executive Square, Suite 950 La Jolla, California 92037 United States | |
| Phone | 619-592-9775 |
| Website | longboardpharma.com |
Stock Details
| Ticker Symbol | LBPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001832168 |
| CUSIP Number | 54300N103 |
| ISIN Number | US54300N1037 |
| Employer ID | 84-5009619 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kevin R. Lind | President, Chief Executive Officer, Secretary and Director |
| Brandi L. Roberts CPA, M.B.A. | Executive Vice President and Chief Financial Officer |
| Dr. Randall E. Kaye M.D. | Executive Vice President and Chief Medical Officer |
| Chadwick J. Orevillo MPH | Executive Vice President and Head of Operations |
| Megan E. Knight | Vice President and Head of Investor Relations |
| Steven W. Spector J.D. | Executive Vice President, Head of Business Development and General Counsel |
| Dr. Anne M. Danks Ph.D. | Vice President and Head of Nonclinical Research & Development |
| Gus Cardenas | Vice President and Head of Quality Assurance |
| Dr. Marco Peters Ph.D. | Vice President and Head of Translational Science |
| Dr. Dewey McLin Ph.D. | Vice President and Head of Medical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2024 | 8-K | Current Report |
| Apr 12, 2024 | ARS | Filing |
| Apr 12, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 12, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 28, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 26, 2024 | 8-K | Current Report |
| Mar 12, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 12, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Mar 12, 2024 | 10-K | Annual Report |
| Mar 12, 2024 | 8-K | Current Report |